SSA
ALNY icon

Schonfeld Strategic Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.37M Sell
31,112
-40,655
-57% -$12.3M 0.03% 434
2026
Q1 		$23.7M Buy
71,767
+26,873
+60% +$9.14M 0.17% 120
2025
Q4 		$17.9M Buy
44,894
+35,185
+362% +$15.6M 0.08% 222
2025
Q3 		$4.43M Sell
9,709
-49,048
-83% -$20M 0.03% 639
2025
Q2 		$19.2M Buy
58,757
+55,675
+1,806% +$15.4M 0.13% 168
2025
Q1 		$832K Sell
3,082
-123,918
-98% -$31.8M 0.01% 1361
2024
Q4 		$29.9M Buy
127,000
+99,133
+356% +$26.1M 0.17% 94
2024
Q3 		$7.66M Sell
27,867
-16,108
-37% -$4.19M 0.05% 380
2024
Q2 		$10.7M Sell
43,975
-191,631
-81% -$30.3M 0.07% 329
2024
Q1 		$35.2M Buy
235,606
+233,653
+11,964% +$39M 0.23% 72
2023
Q4 		$374K Sell
1,953
-40,154
-95% -$6.84M ﹤0.01% 1370
2023
Q3 		$7.46M Buy
42,107
+39,641
+1,608% +$7.56M 0.06% 437
2023
Q2 		$468K Sell
2,466
-12,770
-84% -$2.53M ﹤0.01% 1246
2023
Q1 		$3.05M Buy
+15,236
New +$3.2M 0.03% 583
2022
Q4 		– Sell
-33,615
Closed -$6.73M – 2557
2022
Q3 		$6.73M Buy
+33,615
New +$6.41M 0.06% 432
2022
Q2 		– Sell
-6,700
Closed -$1.09M – 2495
2022
Q1 		$1.09M Buy
+6,700
New +$1.02M 0.01% 944
2021
Q3 		– Sell
-18,968
Closed -$3.22M – 2128
2021
Q2 		$3.22M Buy
18,968
+10,868
+134% +$1.59M 0.03% 572
2021
Q1 		$1.14M Buy
+8,100
New +$1.22M 0.01% 840
2019
Q3 		– Sell
-73,600
Closed -$5.34M – 1005
2019
Q2 		$5.34M Buy
73,600
+10,900
+17% +$836K 0.19% 133
2019
Q1 		$5.86M Buy
62,700
+47,700
+318% +$3.99M 0.2% 133
2018
Q4 		$1.09M Sell
15,000
-51,500
-77% -$3.96M 0.04% 460
2018
Q3 		$5.82M Hold
66,500
– – 0.26% 111
2018
Q2 		$6.55M Buy
66,500
+51,500
+343% +$5.11M 0.36% 78
2018
Q1 		$1.79M Sell
15,000
-3,575
-19% -$461K 0.13% 218
2017
Q4 		$2.36M Buy
+18,575
New +$2.33M 0.19% 147
2016
Q4 		– Sell
-25,618
Closed -$1.74M – 536
2016
Q3 		$1.74M Buy
+25,618
New +$1.81M 0.3% 86

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schonfeld Strategic Advisors's ALNY Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 57% in Q2 2026, selling an estimated $12.3M and leaving 31,112 shares worth $9.37M. The position accounts for 0.03% of the portfolio, ranked #434.

Schonfeld Strategic Advisors first reported a position in ALNY in Q3 2016 and has held it in 26 quarters since. The position peaked at $35.2M in Q1 2024. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Schonfeld Strategic Advisors held 31,112 shares of Alnylam Pharmaceuticals worth $9.37M as of Q2 2026.
  • Schonfeld Strategic Advisors sold 40,655 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.3M.
  • Alnylam Pharmaceuticals made up 0.03% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #434 holding.
  • Schonfeld Strategic Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 26 quarters since.
  • Schonfeld Strategic Advisors's Alnylam Pharmaceuticals position peaked at $35.2M in Q1 2024.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.